Skip to Main Content

Paper Details

Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Diabetes, Obesity and Metabolism
9
2018
CONCLUSIONS, Gemigliptin, HbA1c, Patients, T2DM, fructosamine, gemigliptin, glucose, glycated albumin, glycated haemoglobin, hypoglycaemia, linagliptin, patients, renal impairment, type 2 diabetes, type 2 diabetes mellitus, urinary albumin, urinary type IV collagen
Author NameAffiliation
Sun Woo KangBusan Paik Hospital Inje University
  • 1 - 1

Datasets

Release 1.2